Summary
Global Markets Direct’s, ‘Nerve Injury - Pipeline Review, H2 2016’, provides an overview of the Nerve Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Nerve Injury
- The report reviews pipeline therapeutics for Nerve Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nerve Injury therapeutics and enlists all their major and minor projects
- The report assesses Nerve Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nerve Injury
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nerve Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Biogen, Inc.
BrainStorm Cell Therapeutics Inc.
Calico LLC
F. Hoffmann-La Roche Ltd.
Human Stem Cells Institute
Medtronic plc
Neuralstem, Inc.
Neurotune AG
SanBio, Inc.
TissueGene, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nerve Injury Overview 7
Therapeutics Development 8
Pipeline Products for Nerve Injury - Overview 8
Pipeline Products for Nerve Injury - Comparative Analysis 9
Nerve Injury - Therapeutics under Development by Companies 10
Nerve Injury - Therapeutics under Investigation by Universities/Institutes 11
Nerve Injury - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nerve Injury - Products under Development by Companies 14
Nerve Injury - Products under Investigation by Universities/Institutes 15
Nerve Injury - Companies Involved in Therapeutics Development 16
Biogen, Inc. 16
BrainStorm Cell Therapeutics Inc. 17
Calico LLC 18
F. Hoffmann-La Roche Ltd. 19
Human Stem Cells Institute 20
Medtronic plc 21
Neuralstem, Inc. 22
Neurotune AG 23
SanBio, Inc. 24
TissueGene, Inc. 25
Nerve Injury - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
3K3A-APC - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CLP-257 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
MDT-15 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Neovasculgen - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
NSI-566 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
NT-1654 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
raxatrigine hydrochloride - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SB-618 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecules for Peripheral Nerve Injury - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Synthetic Peptides to Inhibit CaMKII for Stroke and Nerve Injury - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
TG-N - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
U-2902 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Nerve Injury - Dormant Projects 67
Nerve Injury - Discontinued Products 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
List of Tables
Number of Products under Development for Nerve Injury, H2 2016 8
Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Nerve Injury - Pipeline by Biogen, Inc., H2 2016 16
Nerve Injury - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016 17
Nerve Injury - Pipeline by Calico LLC, H2 2016 18
Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 19
Nerve Injury - Pipeline by Human Stem Cells Institute, H2 2016 20
Nerve Injury - Pipeline by Medtronic plc, H2 2016 21
Nerve Injury - Pipeline by Neuralstem, Inc., H2 2016 22
Nerve Injury - Pipeline by Neurotune AG, H2 2016 23
Nerve Injury - Pipeline by SanBio, Inc., H2 2016 24
Nerve Injury - Pipeline by TissueGene, Inc., H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Nerve Injury - Dormant Projects, H2 2016 67
Nerve Injury - Discontinued Products, H2 2016 68
List of Figures
Number of Products under Development for Nerve Injury, H2 2016 8
Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Targets, H2 2016 27
Number of Products by Stage and Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Routes of Administration, H2 2016 31
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 33
Number of Products by Stage and Molecule Types, H2 2016 33
